Continuous Weekly Adalimumab Is the Optimal Long-Term Strategy for Patients With Moderate-to-Severe Hidradenitis Suppurativa: Results from the PIONEER Open Label Extension Trial. J of Skin 2017, 1 (3.1), s129. https://doi.org/10.25251/skin.1.supp.128.